ArticleScientific reports2025
Association between serum Klotho levels and thrombocytosis in aging adults based on evidence from the National Health and Nutrition Examination Survey.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of soluble alpha-klotho as a novel biomarker for characterizing children with autism spectrum disorder in Kurdistan, Iraq.World journal of clinical pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Klotho, a protein primarily expressed in the kidneys and brain, plays a critical role in aging, vascular health, and various metabolic processes. Lower serum Klotho levels have been associated with several chronic diseases, including cardiovascular disease, diabetes, and kidney disease. Although the role of Klotho in platelet regulation remains underexplored, thrombocytosis may be influenced by Klotho levels. Investigating this relationship could offer new insights into thrombocytosis pathogenesis. This study aimed to examine the relationship between serum Klotho levels and thrombocytosis in a U.S. cohort. We hypothesized that lower Klotho levels would be associated with an increased risk of thrombocytosis, potentially providing a novel perspective on thrombocytosis regulation. We conducted a cross-sectional analysis of data from 12,700 participants in the NHANES 2007-2016 cohort. Multivariate logistic regression models were used to assess the association between serum Klotho levels and thrombocytosis, adjusting for relevant covariates. Of the 12,700 participants, 86 had thrombocytosis. The thrombocytosis group had significantly lower mean serum Klotho levels compared to the non-thrombocytosis group (p < 0.01). After adjusting for confounders, an inverse association between serum Klotho levels and thrombocytosis was observed (odds ratio 0.89, 95% CI 0.82-0.97, p = 0.007). Compared to the lowest Klotho quartile (≤ 700.7 pg/ml), the adjusted odds ratios for thrombocytosis in the second (700.8-915.3 pg/ml) and third (≥ 915.4 pg/ml) quartiles were 0.6 (95% CI: 0.36-1.01, p = 0.055) and 0.49 (95% CI: 0.29-0.84, p = 0.01), respectively. Our findings suggest an inverse correlation between serum Klotho levels and thrombocytosis in adults aged 40 and older. These results highlight the potential role of Klotho in thrombocytosis regulation, and future longitudinal studies are needed to establish causality and explore the underlying mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.